Establishing a platform for immunotherapy: Clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 6, 2005, Pages 472-483

  Sportés, Claude ^a   McCarthy, Nicole J ^b   Hakim, Frances ^a   Steinberg, Seth M ^a   Liewehr, David J ^a   Weng, David ^c   Kummar, Shivaani ^a   Gea Banacloche, Juan ^a   Chow, Catherine K ^d   Dean, Robert M ^a   Castro, Kathleen M ^a   Marchigiani, Donna ^d   Bishop, Michael R ^a   Fowler, Daniel H ^a   Gress, Ronald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Autologous stem cell transplantation; Breast cancer; High dose chemotherapy; Immune reconstitution

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; PACLITAXEL; PAMIDRONIC ACID; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HEMATURIA; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; LEUKOENCEPHALOPATHY; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PROSPECTIVE STUDY; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; RECOVERY OF FUNCTION; TRANSPLANTATION, AUTOLOGOUS; VACCINATION;

EID: 19944384599     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.03.010     Document Type: Article

References (34)

1. I.C. Henderson D.F. Hayes R. Gelman Dose-response in the treatment of breast cancer: A critical review J Clin Oncol 6 1988 1501-1515
2. E. Frei III G.P. Canellos Dose: A critical factor in cancer chemotherapy Am J Med 69 1980 585-594
3. S. Rodenhuis M. Bontenbal L.V. Beex et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer N Engl J Med 349 2003 7-16
4. S. Rodenhuis M. Bontenbal L. Beex et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes [abstract] Proc Am Soc Cancer Res 19 2000
5. J.P. Crown M. Lind A. Gould et al. High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients with breast cancer (BC) and 4 or more involved axillary lymph nodes: The Anglo-Celtic I study [abstract] Proc Am Soc Cancer Res 21 2002 42a
6. The Scandinavian Breast Cancer Study Group 9401 Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy [abstract] Proc Am Soc Clin Oncol 18 1999 2a
7. W.P. Peters G. Rosner J. Vredenburgh et al. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstract] Proc Am Soc Clin Oncol 18 1999 1a
8. G.N. Hortobagyi A.U. Buzdar R.L. Theriault et al.Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma J Natl Cancer Inst 92 2000 225-233
9. S. Rodenhuis D.J. Richel E. van der et al. Wall Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement Lancet 352 1998 515-521
10. W.P. Peters R. Jones J. Vredenburgh A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) [abstr] Proc Am Soc Clin Oncol 15 1996 121
11. J.P. Lotz H. Cure M. Janvier et al.High dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol PEGASE [abstr] Proc Am Soc Clin Oncol 18 1999 43a
12. E.A. Stadtmauer A. O'Neill L.J. Goldstein et al. Philadelphia Bone Marrow Transplant Group Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer N Engl J Med 342 2000 1069-1076
13. M.E. Dudley J.R. Wunderlich P.F. Robbins et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850-854
14. N.C.P. Cross L. Feng A. Chase et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation Blood 82 1993 1929-1936
15. P. Schmid H. Samonigg T. Nitsch et al. Randomized trial of upfront tandem high dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer [abstract] Proc Am Soc Clin Oncol 21 2002
16. P. Biron M. Durand H. Roche et al. High-dose thiotepa (TP), cyclophosphamide (CPM), and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocol [abstract] Proc Am Soc Clin Oncol 21 2002 168a
17. Y. Tokuda T. Tajima M. Narabayashi Randomized phase III study of HDC (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer [abstract] Proc Am Soc Clin Oncol 20 2001 38a
18. H. Roche P. Pouillart N. Meyer Adjuvant HDC (HDC) improves early outcome for high-risk (N < 7) breast cancer patients: The Pegase 01 trial [abstract] Proc Am Soc Clin Oncol 20 2001 26a
19. J.G. Schrama I.F. Faneyte J.H. Schornagel et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up Ann Oncol 13 2002 689-698
20. M.S. Tallman R. Gray N.J. Robert et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med 349 2003 17-26
21. C.L. Mackall T.A. Fleisher M.R. Brown et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy N Engl J Med 332 1995 143-149
22. C.L. Mackall T.A. Fleisher M.R. Brown et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer Blood 84 1994 2221-2228
23. C.L. Mackall L. Granger M.A. Sheard R. Cepeda R.E. Gress T-cell regeneration after bone marrow transplantation-Differential CD45 isoform expression on thymic-derived versus thymic-independent progeny Blood 82 1993 2585-2594
24. C.L. Mackall R.E. Gress Pathways of T-cell regeneration in mice and humans: Implications for bone marrow transplantation and immunotherapy Immunol Rev 157 1997 61-72
25. C.L. Mackall C.V. Bare L.A. Granger et al. Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing J Immunol 156 1996 4609-4616
26. I. Borrello E.M. Sotomayor F.M. Rattis et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines Blood 95 2000 3011-3019
27. A.W. Tolcher K.H. Cowan M.H. Noone et al. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients J Clin Oncol 14 1996 95-102
28. H.M. Lazarus R. Gray N. Ciobanu J. Winter R.S. Weiner Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: An Eastern Cooperative Oncology Group (ECOG) study Bone Marrow Transplant 14 1994 443-448
29. E. Kaplan P. Meier Non-parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457-481
30. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163-170
31. K.H. Antman P.A. Rowlings W.P. Vaughan et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America J Clin Oncol 15 1997 1870-1879
32. Hakim FT, Memom SA, Cepeda R, et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest. In press.
33. F.T. Hakim R. Cepeda S. Kaimei et al. Constraints on CD4 recovery postchemotherapy in adults thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells Blood 90 1997 3789-3798
34. Mackall CL, Fleisher TA, Brown MR, et al. Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997;89:3700-3707.